𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study

✍ Scribed by Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, Barton A.

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
283 KB
Volume
21
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily Γ— 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the maximal tolerated dose was reached. A total of 75 courses were administered to 26 children. The major toxicity was myelosuppression, of which neutropenia and thrombocytopenia were most prominent. Rash, mucositis, and transient liver enzyme elevations were infrequently seen. Responses were observed in children with brainstem glioma, neuroblastoma, and renal cell carcinoma. The recommended Phase II dose using this schedule is 9.2–11 mg/m^2^/day depending on how heavily the patient has been treated prior to initiating this therapy. Β© 1993 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

Cisplatin in recurrent pediatric brain t
Cisplatin in recurrent pediatric brain tumors A pog phase II study a pediatric oncology group study
✍ Charles L. Sexauer; Atiya Khan; Peter C. Burger; Jeffrey P. Krischer; Jan Van Ey πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

Forty-six evaluable pediatric patients with primary recurrent brain tumors resistant to standard therapy were treated with cisplatin, 60 mg/m\*/day, X2 days every 3 to 4 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses, documented by computed tomography (CT) sca

Phase I study of a 120-hour continuous i
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study
✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

5-fluorouracil and cis-platinum in the t
5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I β€” II study
✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase II investigation of docetaxel in p
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors : A report from the Children's Oncology Group
✍ Ted Zwerdling; Mark Krailo; Philip Monteleone; Rebecca Byrd; Judith Sato; Rose D πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie

Phase I study of fotemustine in pediatri
Phase I study of fotemustine in pediatric patients with refractory brain tumors
✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 184 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res